Clinico-molecular characteristics and enhanced efficacy of immune checkpoint inhibitors in <i>TP53</i> -mutated advanced biliary tract cancer.
Taro Shibuki(National Cancer Center Hospital East), Masafumi Ikeda(National Cancer Center Hospital East), Oluseyi Abidoye(Mayo Clinic), Yoshiaki Nakamura(National Cancer Center Hospital East), Yasuyuki Kawamoto(Hokkaido University Hospital), Binbin Zheng-Lin(WinnMed), Hideaki Bando(Aichi Cancer Center), Shinji Itoh(Kyushu University), Cody Eslinger(WinnMed), Makoto Ueno(Kanagawa Prefectural Hospital Organization), Takao Fujisawa(National Cancer Center Hospital East), Takayuki Yoshino(University of Tsukuba), Chigusa Morizane, Tanios Bekaii‐Saab(WinnMed), Ryne C. Ramaker(Duke Medical Center), Mitsuho Imai(National Cancer Center Hospital East), Celine Hoyek(Mayo Clinic Hospital), Angelo Pirozzi(Humanitas University), Madhuri Gottam, John H. Strickler(Duke Medical Center)
Cited by 0
Related Papers
Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer
|International Journal of Clinical Oncology|2017|2.5k
Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2019 for the treatment of colorectal cancer
|International Journal of Clinical Oncology|2019|2k
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
|The Lancet|2020|1.8k
Encorafenib, Binimetinib, and Cetuximab in <i>BRAF</i> V600E–Mutated Colorectal Cancer
|New England Journal of Medicine|2019|1.5k
Localised colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2020|1.3k